{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:22:07Z","timestamp":1795029727287,"version":"4.10.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02180-3","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:41:44Z","timestamp":1761813704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience"],"prefix":"10.1186","volume":"26","author":[{"given":"Anna P.","family":"Andreou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand","family":"Al-Rawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Briscoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Kilner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Lambru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2180_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37:631\u2013649","journal-title":"Neurol Clin"},{"key":"2180_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"key":"2180_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","volume":"64","author":"F Cohen","year":"2024","unstructured":"Cohen F, Brooks CV, Sun D et al (2024) Prevalence and burden of migraine in the United States: a systematic review. Headache 64:516\u2013532","journal-title":"Headache"},{"key":"2180_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01753-y","volume":"25","author":"R Oliveira","year":"2024","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F (2024) CGRP-targeted medication in chronic migraine - systematic review. J Headache Pain 25:51","journal-title":"J Headache Pain"},{"key":"2180_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12121612","volume":"12","author":"JP Rissardo","year":"2022","unstructured":"Rissardo JP, Caprara ALF (2022) Gepants for acute and preventive migraine treatment: a narrative review. Brain Sci 12:1612","journal-title":"Brain Sci"},{"key":"2180_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567","volume":"8","author":"B Baker","year":"2020","unstructured":"Baker B, Schaeffler B, Beliveau M et al (2020) Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect 8:e00567","journal-title":"Pharmacol Res Perspect"},{"key":"2180_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02714-1","volume":"22","author":"J Ailani","year":"2022","unstructured":"Ailani J, McAllister P, Winner PK (2022) Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial. BMC Neurol 22:205","journal-title":"BMC Neurol"},{"key":"2180_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241\u2013254","journal-title":"Cephalalgia"},{"key":"2180_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94:e1365\u2013e1377","journal-title":"Neurology"},{"key":"2180_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo- controlled, phase 3b trial. Lancet Neurol 21:597\u2013607","journal-title":"Lancet Neurol"},{"key":"2180_CR11","unstructured":"Eptinezumab for preventing migraine.Technology appraisal guidance National Institute for Health and Care Excellence (NICE). Access date: June 2025 https:\/\/www.nice.org.uk\/guidance\/ta871"},{"key":"2180_CR12","unstructured":"NICE Technology Appraisal Guidance Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Access date: June 2025 https:\/\/www.nice.org.uk\/guidance\/TA260"},{"key":"2180_CR13","unstructured":"Howell D.C. (2007) Statistical methods for psychology (6th ed) Belmont, California: Duxbury Press 65-79"},{"key":"2180_CR14","volume-title":"Using multivariant statistics","author":"BG Tabachnick","year":"2007","unstructured":"Tabachnick BG, Fidel LS (2007) Using multivariant statistics, 5th edn. Allyn and Bacon, Boston","edition":"5"},{"key":"2180_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European migraine & headache alliance (EMHA). J Headache Pain 21:76","journal-title":"J Headache Pain"},{"key":"2180_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","volume":"23","author":"AP Andreou","year":"2022","unstructured":"Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R, Lambru G (2022) Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain 23:139","journal-title":"J Headache Pain"},{"key":"2180_CR17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40120-023-00521-5","volume":"12","author":"Y Bader","year":"2023","unstructured":"Bader Y, Suliman R, Harb M, Santos V, Al Qaisi I, Alsaadi T (2023) Effectiveness and safety of eptinezumab in episodic and chronic migraine headache in the UAE: a retrospective study. Neurol Ther 12:1683\u20131693","journal-title":"Neurol Ther"},{"key":"2180_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13095-z","volume":"272","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Aurilia C, Egeo G (2025) A 24-week prospective, multicenter, real-world study on eptinezumab\u2019s effectiveness and safety in migraine prevention (EMBRACE II). J Neurol 272:382","journal-title":"J Neurol"},{"key":"2180_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32","journal-title":"J Headache Pain"},{"key":"2180_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61","journal-title":"J Headache Pain"},{"key":"2180_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","volume":"101","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2023) Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study. Neurology 101:482\u2013488","journal-title":"Neurology"},{"key":"2180_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01323-6","volume":"22","author":"A Scheffler","year":"2021","unstructured":"Scheffler A, Schenk H, Wurthmann S et al (2021) CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. J Headache Pain 22:111","journal-title":"J Headache Pain"},{"key":"2180_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000547","volume":"6","author":"JC Ray","year":"2024","unstructured":"Ray JC, Dalic L, Baker J, Cheng S, Hutton EJ, Matharu M (2024) Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study. BMJ Neurol Open 6:e000547","journal-title":"BMJ Neurol Open"},{"key":"2180_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s13311-023-01394-0","volume":"20","author":"G Lambru","year":"2023","unstructured":"Lambru G, Caponnetto V, Hill B et al (2023) Long-term effect of switching from an anti-CGRP receptor to an anti-CGRP ligand antibody in treatment-refractory chronic migraine: a prospective real-world analysis. Neurotherapeutics 20:1284\u20131293","journal-title":"Neurotherapeutics"},{"key":"2180_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01593-2","volume":"24","author":"A Straube","year":"2023","unstructured":"Straube A, Broessner G, Gaul C et al (2023) Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the finesse study. J Headache Pain 24:59","journal-title":"J Headache Pain"},{"key":"2180_CR26","doi-asserted-by":"publisher","first-page":"333102424128887","DOI":"10.1177\/03331024241288875","volume":"44","author":"P Triller","year":"2024","unstructured":"Triller P, Blessing VN, Overeem LH et al (2024) Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia 44:3331024241288875","journal-title":"Cephalalgia"},{"issue":"10203","key":"2180_CR27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040","journal-title":"Lancet"},{"key":"2180_CR28","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19:814\u2013825","journal-title":"Lancet Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02180-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02180-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02180-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:41:45Z","timestamp":1761813705000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02180-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2180"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02180-3","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"APA received speakers\u2019 honoraria by Abbvie, Pfizer, Teva; research support to institution by Brain Research UK; Medical Research Council; Abbvie; Pfizer; advisory board of Neuresta INC; relationship with scientific journals: Editorial Board Cephalalgia; ToxinsSociety Leadership\/Board position: Trustee of the International Headache Society; Chair Headache SIG of British Pain Society; Lead of the National Audit for Headache Disorders\/National Audit of Migraine, UK.BH: received speakers\/advisory board\u2019s honoraria from TEVA, Organon, Lundbeck, Pfizer, Abbvie, eNeura.RAR, MM, IS have nothing to declare.JB: received speaker\/advisory board\u2019s honoraria from TEVA and PfizerRK: received speaker\u2019s honoraria from Abbvie and Pfizer and personal fees from TEVA GL : he is the Co-Chair of the Medical Advisory Board of the Trigeminal Neuralgia and facial Pain Charity (TNA) UK; he received speaker\u2019s honoraria from Pfizer, Teva, Eli Lilly, Lundbeck, Dr Reddy\u2019s laboratories; he served on the advisory boards of Pfizer, Teva, Eli Lilly, Lundbeck, Dr Reddy\u2019s laboratories\u2019; he participated in clinical trials as principal investigator for Novartis, Eli Lilly, Teva, Noema.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}